BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 8758903)

  • 1. A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals.
    Berman DB; Costalas J; Schultz DC; Grana G; Daly M; Godwin AK
    Cancer Res; 1996 Aug; 56(15):3409-14. PubMed ID: 8758903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer.
    Neuhausen S; Gilewski T; Norton L; Tran T; McGuire P; Swensen J; Hampel H; Borgen P; Brown K; Skolnick M; Shattuck-Eidens D; Jhanwar S; Goldgar D; Offit K
    Nat Genet; 1996 May; 13(1):126-8. PubMed ID: 8673092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%.
    Oddoux C; Struewing JP; Clayton CM; Neuhausen S; Brody LC; Kaback M; Haas B; Norton L; Borgen P; Jhanwar S; Goldgar D; Ostrer H; Offit K
    Nat Genet; 1996 Oct; 14(2):188-90. PubMed ID: 8841192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer.
    Shiri-Sverdlov R; Oefner P; Green L; Baruch RG; Wagner T; Kruglikova A; Haitchick S; Hofstra RM; Papa MZ; Mulder I; Rizel S; Bar Sade RB; Dagan E; Abdeen Z; Goldman B; Friedman E
    Hum Mutat; 2000 Dec; 16(6):491-501. PubMed ID: 11102978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.
    Roa BB; Boyd AA; Volcik K; Richards CS
    Nat Genet; 1996 Oct; 14(2):185-7. PubMed ID: 8841191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA2 germline mutations in male breast cancer cases and breast cancer families.
    Couch FJ; Farid LM; DeShano ML; Tavtigian SV; Calzone K; Campeau L; Peng Y; Bogden B; Chen Q; Neuhausen S; Shattuck-Eidens D; Godwin AK; Daly M; Radford DM; Sedlacek S; Rommens J; Simard J; Garber J; Merajver S; Weber BL
    Nat Genet; 1996 May; 13(1):123-5. PubMed ID: 8673091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients.
    Tobias DH; Eng C; McCurdy LD; Kalir T; Mandelli J; Dottino PR; Cohen CJ
    Gynecol Oncol; 2000 Aug; 78(2):148-51. PubMed ID: 10926794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel.
    Figer A; Irmin L; Geva R; Flex D; Sulkes J; Sulkes A; Friedman E
    Br J Cancer; 2001 Feb; 84(4):478-81. PubMed ID: 11207041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The I1307K APC mutation does not predispose to colorectal cancer in Jewish Ashkenazi breast and breast-ovarian cancer kindreds.
    Petrukhin L; Dangel J; Vanderveer L; Costalas J; Bellacosa A; Grana G; Daly M; Godwin AK
    Cancer Res; 1997 Dec; 57(24):5480-4. PubMed ID: 9407954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel.
    Vazina A; Baniel J; Yaacobi Y; Shtriker A; Engelstein D; Leibovitz I; Zehavi M; Sidi AA; Ramon Y; Tischler T; Livne PM; Friedman E
    Br J Cancer; 2000 Aug; 83(4):463-6. PubMed ID: 10945492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.
    Goggins M; Schutte M; Lu J; Moskaluk CA; Weinstein CL; Petersen GM; Yeo CJ; Jackson CE; Lynch HT; Hruban RH; Kern SE
    Cancer Res; 1996 Dec; 56(23):5360-4. PubMed ID: 8968085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
    Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P
    Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
    Wolf I; Laitman Y; Rubinek T; Abramovitz L; Novikov I; Beeri R; Kuro-O M; Koeffler HP; Catane R; Freedman LS; Levy-Lahad E; Karlan BY; Friedman E; Kaufman B
    Oncogene; 2010 Jan; 29(1):26-33. PubMed ID: 19802015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High frequency of BRCA1 and BRCA2 germline mutations in Ashkenazi Jewish ovarian cancer patients, regardless of family history.
    Beller U; Halle D; Catane R; Kaufman B; Hornreich G; Levy-Lahad E
    Gynecol Oncol; 1997 Nov; 67(2):123-6. PubMed ID: 9367693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double heterozygosity for mutations in the BRCA1 and BRCA2 genes in a breast cancer patient.
    Tsongalis GJ; Linfert DR; Johnson RC; Ackroyd R; Berman MM; Ricci A
    Arch Pathol Lab Med; 1998 Jun; 122(6):548-50. PubMed ID: 9625424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals.
    Struewing JP; Abeliovich D; Peretz T; Avishai N; Kaback MM; Collins FS; Brody LC
    Nat Genet; 1995 Oct; 11(2):198-200. PubMed ID: 7550349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families.
    Phelan CM; Kwan E; Jack E; Li S; Morgan C; Aubé J; Hanna D; Narod SA
    Hum Mutat; 2002 Nov; 20(5):352-7. PubMed ID: 12402332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low incidence of BRCA2 mutations in breast carcinoma and other cancers.
    Teng DH; Bogden R; Mitchell J; Baumgard M; Bell R; Berry S; Davis T; Ha PC; Kehrer R; Jammulapati S; Chen Q; Offit K; Skolnick MH; Tavtigian SV; Jhanwar S; Swedlund B; Wong AK; Kamb A
    Nat Genet; 1996 Jun; 13(2):241-4. PubMed ID: 8640236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
    Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
    Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.